Austrian Apheresis Association(AAA)

EuroMedix is a partner with the Austrian Apheresis Association (Österreichische Apheresegesellschaft).

EuroMedix is committed to reducing cardiovascular events, among others through health screening systems and projects (primary and secondary prevention).

AAA: Reductions in cardiovascular events by 90% and more are possible

Helmut Sinzinger, AAA President and former Head of the University Clinic for Nuclear Medicine of the Medical University of Vienna [Univ.-Klinik für Nuklearmedizin der MedUni Wien]: “Apheresis leads to a massive reduction of cardiovascular events by some 90%, resulting in a virtually normal life expectancy for patients. Whereas previously, the treatment was given only to patients unable to achieve a sufficient lowering of cholesterol despite maximal drug intervention, today new indications have been added.” These include the incompatibility of all available lipid-lowering agents and even extremely elevated lipoprotein(a) levels, which is considered an independent risk factor for the development of atherosclerosis in cases of proven clinically-manifest atherosclerosis.

Since it can remove not only LDL cholesterol but all lipoproteins that promote atherosclerosis, the therapy is now referred to as a “lipoprotein apheresis”. “Under a strict indication scheme, as defined in the 1st Austrian Apheresis Consensus, lipoprotein apheresis is a new, highly effective treatment option for extreme cases,” concludes Sinzinger.

The importance of apheresis in transplantation medicine, autoimmune diseases and the future prospects of apheresis in combating asthma and severe allergic diseases

EuroMedix provides point-of-care products and services at the cutting edge of technology, with the aim of facilitating the early detection and prevention of health problems, and monitoring existing conditions.

CHARM⁽¹⁾ concept

(1) Cardiometabolic Health & Advanced Risk Management

The focus of EuroMedix is providing health screening systems and projects for

• the early prevention of widespread diseases (primary prevention)
• the early detection of risk factors and disease (secondary prevention)
• the care of patients with an existing disease, to improve the prognosis and outcome (secondary prevention)

Another dimension in cardiovascular-health and advanced risk management is the development of new technologies to determine direct LDL cholesterol levels (fasting not required), lipoprotein(a), vascular age, arterial stiffness, AGEs (Advanced Glycation End-products), etc.